Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1970 3
1971 1
1973 2
1974 6
1975 2
1976 11
1977 9
1978 2
1979 4
1980 6
1981 17
1982 5
1983 6
1984 5
1985 7
1986 7
1987 10
1988 10
1989 8
1990 1
1991 6
1992 4
1993 11
1994 14
1995 8
1996 11
1997 15
1998 18
1999 11
2000 16
2001 17
2002 14
2003 23
2004 24
2005 33
2006 29
2007 41
2008 40
2009 11
2010 5
2011 12
2012 13
2013 14
2014 14
2015 7
2016 10
2017 9
2018 9
2019 6
2020 5
2021 8
2022 8
2023 9
2024 20
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

579 results

Results by year

Filters applied: . Clear all
Page 1
Intrahepatic sarcomatoid cholangiocarcinoma.
Kaibori M, Kawaguchi Y, Yokoigawa N, Yanagida H, Takai S, Kwon AH, Uemura Y, Kamiyama Y. Kaibori M, et al. Among authors: kamiyama y. J Gastroenterol. 2003;38(11):1097-101. doi: 10.1007/s00535-003-1203-y. J Gastroenterol. 2003. PMID: 14673730 Review.
Remimazolam anaphylaxis during anesthesia induction.
Tsurumi K, Takahashi S, Hiramoto Y, Nagumo K, Takazawa T, Kamiyama Y. Tsurumi K, et al. Among authors: kamiyama y. J Anesth. 2021 Aug;35(4):571-575. doi: 10.1007/s00540-021-02934-8. Epub 2021 May 28. J Anesth. 2021. PMID: 34050439
Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology.
Maeda T, Najima Y, Kamiyama Y, Nakao S, Ozaki Y, Nishio H, Tsuchihashi K, Ichihara E, Miumra Y, Endo M, Maruyama D, Yoshinami T, Susumu N, Takekuma M, Motohashi T, Ito M, Baba E, Ochi N, Kubo T, Uchino K, Kimura T, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T, Yano S. Maeda T, et al. Among authors: kamiyama y. Int J Clin Oncol. 2024 May;29(5):535-544. doi: 10.1007/s10147-023-02465-0. Epub 2024 Mar 18. Int J Clin Oncol. 2024. PMID: 38494578 Free PMC article.
Biodistribution studies for cell therapy products: Current status and issues.
Kamiyama Y, Naritomi Y, Moriya Y, Yamamoto S, Kitahashi T, Maekawa T, Yahata M, Hanada T, Uchiyama A, Noumaru A, Koga Y, Higuchi T, Ito M, Komatsu H, Miyoshi S, Kimura S, Umeda N, Fujita E, Tanaka N, Sugita T, Takayama S, Kurogi A, Yasuda S, Sato Y. Kamiyama Y, et al. Regen Ther. 2021 Jul 12;18:202-216. doi: 10.1016/j.reth.2021.06.005. eCollection 2021 Dec. Regen Ther. 2021. PMID: 34307798 Free PMC article. Review.
HOMENAGEM PÓSTUMA: DRA. WANDA DE AGUIAR HORTA.
Kamiyama Y. Kamiyama Y. Rev Esc Enferm USP. 1981 Aug;15(2):125. doi: 10.1590/0080-6234198101500200125. Rev Esc Enferm USP. 1981. PMID: 28768007 Portuguese. No abstract available.
Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
Ozaki Y, Yokoe T, Yoshinami T, Nozawa K, Nishio H, Tsuchihashi K, Ichihara E, Miura Y, Endo M, Yano S, Maruyama D, Susumu N, Takekuma M, Motohashi T, Ito M, Baba E, Ochi N, Kubo T, Uchino K, Kimura T, Kamiyama Y, Nakao S, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T. Ozaki Y, et al. Among authors: kamiyama y. Int J Clin Oncol. 2024 May;29(5):551-558. doi: 10.1007/s10147-024-02499-y. Epub 2024 Mar 25. Int J Clin Oncol. 2024. PMID: 38526621
Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022.
Ichihara E, Ochi N, Makimoto G, Kudo K, Harada D, Ozaki Y, Nishio H, Tsuchihashi K, Miura Y, Endo M, Yano S, Maruyama D, Yoshinami T, Susumu N, Takekuma M, Motohashi T, Ito M, Baba E, Uchino K, Kimura T, Kamiyama Y, Nakao S, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T, Kubo T. Ichihara E, et al. Among authors: kamiyama y. Int J Clin Oncol. 2024 Apr;29(4):355-362. doi: 10.1007/s10147-024-02469-4. Epub 2024 Feb 14. Int J Clin Oncol. 2024. PMID: 38353907
Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
Yoshinami T, Nozawa K, Yokoe T, Ozaki Y, Nishio H, Tsuchihashi K, Ichihara E, Miura Y, Endo M, Yano S, Maruyama D, Susumu N, Takekuma M, Motohashi T, Ito M, Baba E, Ochi N, Kubo T, Uchino K, Kimura T, Kamiyama Y, Nakao S, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T. Yoshinami T, et al. Among authors: kamiyama y. Int J Clin Oncol. 2024 Jun;29(6):681-688. doi: 10.1007/s10147-024-02504-4. Epub 2024 Apr 23. Int J Clin Oncol. 2024. PMID: 38649648
Therapeutic use of granulocyte colony-stimulating factor (G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.
Tsuchihashi K, Ito M, Okumura Y, Nio K, Ozaki Y, Nishio H, Ichihara E, Miura Y, Endo M, Yano S, Maruyama D, Yoshinami T, Susumu N, Takekuma M, Motohashi T, Ochi N, Kubo T, Uchino K, Kimura T, Kamiyama Y, Nakao S, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T, Baba E. Tsuchihashi K, et al. Among authors: kamiyama y. Int J Clin Oncol. 2024 Jun;29(6):700-705. doi: 10.1007/s10147-024-02541-z. Epub 2024 May 2. Int J Clin Oncol. 2024. PMID: 38696053
579 results